Example: Heart Attack

Search clinical trials for: D 23129

Total 28 results

NCT01823159

Completed

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

Conditions: Epilepsy
NCT02450552

Completed

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Conditions: Amyotrophic Lateral Sclerosis
NCT01777139

Completed

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Conditions: Epilepsy
NCT02149836

Completed

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Conditions: Major Depressive Disorder; Depression
NCT01668654

Terminated

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Conditions: Epilepsy
NCT00310388

Terminated

Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Conditions: Epilepsy
NCT00232596

Completed

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Conditions: Seizures
NCT01691872

Withdrawn

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Conditions: Epilepsy, Partial
NCT00235755

Completed

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Conditions: Seizures
NCT01336621

Completed

Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)

Conditions: Epilepsy
NCT01494584

Terminated

Study in Pediatric Subjects With Epilepsy

Conditions: Epilepsy
NCT01227902

Completed

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

Conditions: Epilepsy
NCT00310375

Completed

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Conditions: Epilepsy
NCT01583036

Completed

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

Conditions: Epilepsy
NCT01607346

Terminated

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Conditions: Epilepsy
NCT01648101

Terminated

Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

Conditions: Epilepsy
NCT03043560

Completed

Study to Treat Major Depressive Disorder With a New Medication

Conditions: Depressive Disorder; Anhedonia
NCT01480609

Completed

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

Conditions: Epilepsy
NCT01462669

Completed

Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

Conditions: Epilepsy
NCT01457989

Completed

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

Conditions: Epilepsy, Partial
NCT00612105

Completed

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Conditions: Postherpetic Neuralgia
NCT01721317

Terminated

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

Conditions: Seizures
NCT01938560

Completed

REMS Retigabine Study

Conditions: Epilepsy
NCT01587339

Completed

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Conditions: Epilepsy
NCT01332513

Completed

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

Conditions: Epilepsy